Summary
A trend toward the modest extension of progression-free survival and overall survival was seen in a subgroup of non–small cell lung cancer patients in this phase 2 randomized double-blind trial of veliparib combined with carboplatin and paclitaxel compared with carboplatin and paclitaxel alone.
- phase 2
- multicenter
- randomized
- double blind
- veliparib
- carboplatin
- paclitaxel
- poly (ADP-ribose) polymerase inhibitors
- PARP
- non–small cell lung cancer
- progression-free survival
- overall survival
- NCT01560104
- oncology clinical trials
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.